introduct
current
worldwid
outbreak
coronaviru
diseas
due
novel
coronaviru
serious
threaten
public
health
number
infect
patient
continu
increas
need
intens
care
unit
admiss
rang
mortal
report
around
higher
valu
elderli
patient
comorbid
moreov
condit
challeng
healthcar
system
outbreak
reach
highest
valu
date
still
avail
treatment
clinic
preclin
evid
suggest
nitric
oxid
benefici
effect
coronavirusmedi
acut
respiratori
syndrom
relat
viricid
effect
time
symptom
onset
develop
sever
respiratori
distress
rel
long
hypothes
high
concentr
inhal
administ
earli
phase
infect
prevent
progress
diseas
novel
coronaviru
first
identifi
china
decemb
today
case
report
death
major
still
concentr
china
infect
spread
across
countri
border
mani
asian
countri
well
europ
usa
posit
singlestrand
rna
viru
belong
famili
coronavirida
current
outbreak
would
result
acquir
abil
viru
undergo
human
human
transmiss
jump
origin
anim
reservoir
like
bat
human
host
caus
respiratori
syndrom
name
rang
mild
involv
upper
airway
sever
pneumonia
acut
respiratori
syndrom
ar
need
mechan
ventil
intens
care
unit
icu
earli
case
seri
risk
critic
care
admiss
rang
higher
valu
elderli
patient
comorbid
chronic
diseas
time
symptom
onset
develop
sever
respiratori
distress
rel
long
median
time
day
patient
remain
state
mild
diseas
character
dri
cough
fever
mild
hypoxia
requir
oxygen
supplement
sever
diseas
necess
icu
develop
outcom
worsen
decis
mortal
rais
moreov
icu
stay
pose
seriou
strain
resourcelimit
hospit
thu
prevent
diseas
progress
mild
phase
would
highli
desir
term
morbid
mortal
improv
healthcar
resourcespar
present
time
proven
etiolog
treatment
ongo
clinic
trial
test
effect
antivir
drug
clinicaltrialsgov
pilot
studi
show
low
dose
inhal
nitric
oxid
abl
shorten
time
ventilatori
support
sar
epidem
sustain
anoth
coronaviru
sarscov
vitro
studi
donor
compound
snitrosonacteylpenicillamin
increas
surviv
rate
vitro
model
sarscov
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
infect
monkey
epitheli
cell
suggest
possibl
viricid
effect
ga
inhal
high
dose
administ
safe
known
potenti
microbicid
effect
invitro
test
specif
viru
recommend
propos
random
clinic
trial
test
effect
inhal
prevent
progress
diseas
administ
earli
stage
multicent
random
clinic
trial
symptom
must
includ
presenc
fever
least
axillari
site
oral
site
rectal
tympan
site
addit
patient
must
spontan
breath
respiratori
rate
least
breath
per
minut
andor
object
persist
cough
consist
symptom
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
patient
without
hypoxia
includ
ga
exchang
ventil
may
assist
mean
continu
posit
airway
pressur
cpap
system
system
noninvas
ventil
niv
posit
endexpiratori
pressur
peep
criteria
exclus
pregnanc
women
fertil
age
test
pregnanc
enrol
presenc
open
tracheostomi
therapi
highflow
nasal
cannula
clinic
contraind
ga
deliveri
judg
attend
physician
hospit
confirm
diagnosi
hour
tabl
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
recoveri
symptom
defin
normal
fever
respiratori
rate
allevi
cough
sustain
least
hour
endpoint
flowchart
studi
present
figur
evalu
patient
continu
day
enrol
sinc
treatment
inhal
lead
increas
plasmat
methemoglobin
blood
level
methemoglobin
monitor
via
noninvas
cooximet
methemoglobin
level
blood
methemoglobin
level
rise
point
studi
inhal
concentr
immedi
stop
subsequ
dose
safeti
reason
also
evalu
level
order
keep
ppm
observ
increas
valu
immedi
interrupt
administr
subsequ
dose
patient
assign
control
group
receiv
ga
therapi
primari
outcom
proport
patient
progress
sever
form
diseas
defin
indic
given
attend
physician
intub
mechan
ventil
first
day
enrol
studi
patient
sever
respiratori
failur
andor
ventilatori
distress
indic
intub
concomit
dni
intub
meet
criteria
primari
endpoint
proport
intub
calcul
day
studi
enrol
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
clinic
inform
includ
medic
histori
laboratori
exam
obtain
medic
chart
prospect
record
discharg
death
collect
studi
variabl
manag
outcom
assessor
use
dedic
patient
file
studytrax
day
follow
patient
discharg
hospit
perform
phone
call
outcom
assessor
treatment
provid
princip
investig
obtain
uniqu
usernam
password
transfer
data
studytrax
page
dedic
studi
data
access
restrict
author
member
team
respons
strict
confidenti
time
sign
inform
consent
kept
secur
place
least
year
studi
complet
base
previous
publish
data
covid
predict
incid
intub
mechan
ventil
howev
novel
natur
studi
enough
data
predict
effect
inhal
primari
outcom
dynam
trend
ongo
outbreak
also
prevent
us
determin
rate
enrol
achiev
tabl
display
sampl
size
calcul
primari
outcom
alpha
level
power
level
differ
scenario
perform
first
analysi
base
patient
evalu
actual
incid
primari
outcom
effect
treatment
actual
rate
enrol
pi
decid
togeth
dsmb
whether
continu
enrol
patient
suffici
rate
enrol
power
achiev
origin
sampl
size
base
result
report
tabl
step
could
repeat
increas
sampl
size
patient
patient
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
statist
analysi
data
analyz
follow
intent
treat
analysi
principl
demograph
clinic
data
present
proport
categor
outcom
mean
plu
standard
deviat
median
plu
interquartil
rang
continu
outcom
comparison
group
made
x
test
fisher
exact
test
categor
variabl
ttest
wilcoxon
ranksum
test
continu
variabl
ttest
normal
distribut
evalu
time
event
outcom
analyz
estim
surviv
curv
treat
nontreat
use
kaplanmei
method
subgroup
analysi
perform
multipl
linear
regress
well
logist
cox
regress
model
adjust
age
pulmonari
comorbid
coadministr
experiment
treatment
data
monitor
data
monitor
princip
investig
pi
collabor
independ
data
safeti
monitor
board
dsmb
pi
dsmb
monitor
advers
event
qualiti
data
provid
recommend
pi
monitor
complianc
safeti
rule
everi
patient
everi
violat
report
dsmb
peripher
center
provid
data
sheet
provid
safeti
rule
instruct
report
everi
violat
coordin
hospit
begin
studi
dsmb
meet
decid
safeti
rule
stop
guidelin
perform
interim
analysi
dsmb
grant
author
stop
trial
point
due
safeti
concern
aim
trial
evalu
whether
high
dose
administ
earli
stage
safe
reduc
prevent
progress
diseas
studi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
open
everi
center
want
particip
interest
particip
studi
pleas
contact
princip
investig
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
